Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating daratumumab for relapsed/refractory precursor B-cell or T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma in pediatric and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Lymphoma
• Precursor B-cell Acute Lymphoblastic Leukemia
• Precursor T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-10-13